Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.P. Wenzel, M.B. Edmond.
Vancomycin-Resistant Staphylococcus aureus: Infection Control Considerations.
Clin Infec Dis, 27 (1998), pp. 245-251
[2.]
M. Rubio Alonso, J. Romero Vivas.
Infecciones por Staphylococcus aureus.
Infecciones por grampositivos, pp. 149-189
[3.]
F. Baquero.
Antibiotic Resistance in Spain: What Can Be Done?.
Clin Infect Dis, 23 (1996), pp. 819-823
[4.]
K. Hiramatsu, N. Aritaka, H. Hanaki, G. Kawasaki, Y. Hosoda, S. Hor, et al.
Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.
Lancet, 350 (1997), pp. 1.670-1.673
[5.]
CDC Update. Staphylococcus aureus with reduced susceptibility to vancomycin.
United States 1997. MMWR, 46 (1997), pp. 813
[6.]
J. García de Lomas.
Grupo Español para Vigilancia de Patógenos Respiratorias. Situación epidemiológica actual y resistencia de los patógenos respiratorios en España.
Med Clin, 110 (1998), pp. 44-51
[7.]
J.D. Heffelfinge, S.F. Dowell, J.H. Jorgensen, K.P. Klugman, L.R. Mabry, D.M. Musher, et al.
and de Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Management of Community-Acquired Pneumonia in the era of Pneumococcal resistance.
Arch Intern Med, 160 (2000), pp. 1.399-1.408
[8.]
F. Baquero, J.A. García Rodríguez, J. García de Lomas, L. Aguilar.
and The Spanish Surveillance Group for Respiratory Pathogens.
Antimicrob Agents Chemother, 43 (1999), pp. 357-359
[9.]
A.H. Uttley, C.H. Collins, J. Naidoo, R.C. George.
Vancomycin-resistant enterococci (letter).
Lancet, 1 (1998), pp. 57-58
[10.]
R. Leclereq, E. Derlot, J. Duval, P. Courvalin.
Plasmid-mediated resistance to vancomycin and teicomplanin in Enterococcus faecium.
N Engl J Med, 319 (1988), pp. 157-161
[11.]
M.J. Struelens.
The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions.
BMJ, 317 (1998), pp. 652-654
[12.]
K.E. Pickerill, J.A. Paladino, J.J. Schentag.
Comparison of the Fluoroquinolones Based on Pharmacokinetic and Pharmacodynamic Parameters.
Pharmacotherapy, 20 (2000), pp. 417-428
[13.]
V.J. Heaton, C.E. Goldsmith, J.E. Ambler, L.M. Fisher.
Activity of Gemifloxacin against Penicillin- and Ciprofloxacin-Resistant Streptococcus pneumoniae Displaying Topoisomerase- and Efflux-Mediated Resitance Mechanisms.
Antimicrob Agents Chemother, 43 (1999), pp. 2.998-3.000
[14.]
P. Ball, R. Wilson, L. Mandell, T. File, J. Kirsch, C. Chinn, et al.
Gemifloxacin long-term outcomes in bronqhitis exacerbations study - An assessment of health outcome benefits in AECB patients following 5 days gemifloxacin therapy. 40th,
[15.]
R. Willon, P. Ball, L. Mandell, T. File, T.J. Henkel, J. Adelglass, et al.
Efficacy of once daily gemifloxacin for 5 days compared with twice daily clarthromycin for 7 days in the treatment of AECB. 40th,
[16.]
B.J. Ferguson, J.B. Anon, K.C. Hendrick, L. Hende, G. Horvai, C. Young.
The Gemifloxacin 009 Study Group. 40th,
[17.]
T.J. Henkel, D. Mckay, C. Young.
Safety of gemifloxacin in patients aged ??65 years with respiratory and urinary tract infections. 40th,
[18.]
EJ. Goldstein, DM. Citron, CV. Merriam.
Linezolid activity compared to those of selected macrolides and other agents aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans.
Antimicrob Agents Chemother, 43 (1999), pp. 1.469-1.474
[19.]
R. Suárez, M. Herrera, M. Rueda, M. Del Cerro, E. Sánchez Yus.
Metástasis cutáneas.
Medicina Integral, 28 (1996), pp. 426-430
[20.]
S.M. Swaney, D.L. Shinabarger, R.D. Schaadt, J.H. Bock, J.L. Slightom, G.E. Zurenko.
Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S,
[21.]
J.E. Conte, J.A. Golden, J.E. Kipps, E. Zurlinden.
Intrapulmonary pharmacokinetics of linezolid. 40th,
[22.]
J.P. Martin, J.T. Herberg, J.G. Slatter, M.J. Dupuis.
Although a novel microtiter- plate assay demonstrates that linezolid (PNU-100766) is a weak, competitive (reversible) inhibitor of human monoamine oxidase (MAO A) no clinical evidence of MAO A inhibition in clinical trials has been observed. 38th,
[23.]
J.M. Hyatt, C.H. Ballow, A. Forrest, M.R. Turnak, D.J. Stalker, J.J. Schentag.
Safety and efficacy of linezolid (PNU-1000766) in erication of nasal Staphylococcus aureus. 38th,
[24.]
M.C. Birmingham, G.S. Zimmer, Sm. Flavin, C.R. Rayner, K.E. Welch, P.F. Smith, et al.
Results of treating bacteremic patients with linezolid in a compassionate use trial for resistant, gram-positive infections. 37th,
[25.]
G.A. Noskin, F. Siddiqui, V. Stosor, L.R. Peterson.
Linezolid (LZD) for the treatment of vancomycin-resistant enterococci (REV) in immunocompromised hosts. 37th,
[26.]
C.S. Hartman, T.S. Leach, R.W. Kaja, R.J. Schaser, W.M. Todd, B. Hafkin.
Linezolid in the treatment of vancomycin-resistant enterococcus: A dose comparative, multicenter phase III trial. 40th,
[27.]
J.W. Chien, M.L. Kucia, R.A. Salata.
Use of Linezolid, an Oxazolidinone, in the Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections.
Clin Infect Dis, 30 (2000), pp. 146-151
[28.]
J.D. Root, M.C. Birmingham, C.R. Rayner, S.M. Flavin, J.J. Schentag.
Results of treating patients with significant, resistant, gram positive, intra-abdominal infections with linezolid. 40th,
[29.]
M.C. Birmingham, C.R. Rayner, S.M. Flavin, A.K. Meagher, J.J. Schentag.
Outcomes of linezolid in patients with malignacies and significant, gram positive infections. 40th,
[30.]
L.D. Dressser, M.C. Birmingham, A.W. Karchmer, C.R. Rayner, S.M. Flavin, J.J. Schentag.
Results of treating infective endocarditis with linezolid. 40th,
[31.]
S.K. Cammarata, R.G. Wunderink, K.A. Hempsall, W.M. Todd, B. Hafkin.
Efficacy of linezolid in patients with nosocomial pneumonia based on severity of illness as determined by baseline APACHE II score. 40th,
[32.]
D.J. Winston, C. Emmanoulides, A. Kroeber, J. Hindler, A. Bruckner, M.C. Territo, et al.
Quinupristin/Dalfopristin Therapy for Infections Due to Vancomycin- Resistant Enterococcus faecium Clin Infec Dis, 30 (2000), pp. 790-797
[33.]
P.K. Linden.
Quinupristin/dalfopristin: A new therapeutic alternative for the treatment of vancomycin-resistant Enterococcus faecium and other serious gram-positive infections.
Today’s Therapeutic Trends, 13 (1997), pp. 137-153
[34.]
R. Leclercq, P. Courvalin.
Bacterial resistance to macrolide, lincosamine, and streptogramin antibiotics by target modification.
Antimicrob Agents Chemother, 35 (1991), pp. 1.267-1.272
[35.]
R. Leclerq, L. Nantas, L. Soussy.
Activity of RP 59500, a new parenteral semisynthetic streptogramin, against stahylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.
J Antimicrob Chemother, 30 (1992), pp. 67-75
[36.]
M. Soltani, J. Philpott-Horward, D. Beighton, N. Woodford.
Two distinct mechanisms confer resistance to quinupristin/dalfopristin (Q/D) in satA-negative Enterococcus faecium (Ef) from animals, raw meat, and hospital patients in the EU. 39th,
[37.]
M. Dowzicky, G.H. Talbot, C. Feger, P. Prokocimer, J. Etienne, R. Leclerq.
Characterization of isolates associated with emerging resistance to quinupristin/ dalfopristin (Synercid) during a worldwide clinical program.
Diagn Microbiol Infect Dis, 37 (2000), pp. 57-62
[38.]
K.T. Luc, P.R. Hsueh, L.J. Teng, H.J. Pan, Y.C. Chen, J.J. Lu, et al.
Quinupristin- dalfopristin resistnce among gram-positive bacteria in Taiwan.
Antimicrob Agents Chemother, 44 (2000), pp. 3.374-3.380
[40.]
R.L. Nichols, D.R. Graham, S.L. Barrie, A. Rodgers, S.E. Wilson, M. Zervos, et al.
Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxazollin or vancomycin.
J Antimicrob Chemother, 44 (1999), pp. 263-273
[41.]
R.H. Drew, J.R. Perfect, L. Srinath, E. Kurkimilis, M. Dowzicky, G.H. Talbot.
Treatment of methicilli-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy.
J Antimicrob Chemother, 46 (2000), pp. 755-784
[42.]
J.Y. Fagon, H. Patrick, D.W. Haas, A. Torres, C. Gibert, W.G. Cheadle, et al.
Treatment of Gram-positive Nosocomial Pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin.
Am J Respir Crit Care Med, 161 (2000), pp. 753-762
[43.]
I. Odenholt, E. Löwdin, O. Cars.
Pharmacodynamics of telithromycin (HMR 3647) against respiratory tract pathogens in vitro. 30th,
[44.]
A. Bryskier.
Novelties in the field of anti-infectives in 1997.
Clin Infec Dis, 27 (1998), pp. 865-883
[45.]
P. Rajagopalan-Levasseur, E. Vallee, A. Bonnefoy, J.F. Chantot, A. Agouridas, A. Bryskier, et al.
HMR 3647: Activity against Legionella pneumophila serogroup 1 (Lp1) in monocytederived macrophages and in experimental guinea pig infection models. 38th,
[46.]
M. Wootton, K.E. Bowker, A. Janowska, H.A. Holt, A.P. Mac Gowan.
In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci.
J Antimicrob Chemother, 44 (1999), pp. 445-453
[47.]
F.J. Boswell, J.M. Andres, J.P. Ashby, C. Fogarty, N.P. Brenwald, R. Wise.
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.
J Antimicrob Chemother, 42 (1998), pp. 703-709
[48.]
K. Malathum, T.M. Coque, K.V. Singh, B.E. Murray.
In vitro activities of two ketolides, HMR3647 and HMR 3004, against Gram-positive bacteria.
Antimicrob Agents Chemother, 43 (1999), pp. 930-936
[49.]
D. Felmingham, M.J. Robbins, R. Cooke, I. Mathias, A. Bryskier.
In vitro activity of HMR 3647 against glycopeptide-resistant isolates of Enterococcus spp. 38th,
[50.]
F. Soriano, R. Fernández-Roblas, R. Calvo, G. García-Calvo, M. Pardeiro, A. Bryskier.
In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. Isolated from clinical specimens.
J Antimicrob Chemother, 42 (1998), pp. 647-649
[51.]
M. Wu, P. Kolonoski, L.E. Bermúdez, L.S. Young.
Efficacy of two ketolides HMR 3004 and HMR 3647, in treatment of disseminated M. avium (MAC) disease in beige mice. 37th,
[52.]
S.L. Pendland, J.L. Prause, M.M. Neuhauser, N. Boyea, J.M. Hackleman, L.H. Danziger.
In vitro activity of ABT-773, a new ketolide antibiotic, alone and in combination with metronidazole, amoxicillin, or tetracycline against Helicobacter pylori. 39th,
[53.]
J. Sucliffe, L. Brennan, J. Duignan, D. Girard, C. Menard, A. Tait-Kamradt.
Certain pneumococcal strains containing an Erm B methaylase display heterotypic resistance to ketolides. 38th,
[54.]
J.M.T. Hamilton-Miller, S. Shah.
Resistance phenotypes in staphylococci to macrolides, lincosamines, ketolide, and streptogramins. 39th,
[55.]
P. Zhong, R. Hammond, Z. Cao, Y. Chen, A. Shortridge, A. Niulis, et al.
Molecular Basis of ABT-773 activity against erm-containing macrolide.resistant S. pneumoniae. 39th,
[56.]
P. Levasseur, E. Vallee, A. Bonnefoy, L. Garry, C. Agouridas, A. Bryskier, et al.
Activity of ketolides HMR 3562 and HMR 3787 against erythromycinsensitive (Ery-S) and-resistant (Ery-Rc) Pneumococci in murine pneumonia models. 39yh,
[57.]
E. Sultan, F. Namour, M.H. Pascual, J. Smith, B. Lenfant.
Penetration of the ketolide, HMR 3647, in cantharidin-induced blister fluid. 38th,
[58.]
I. García, A. Pascula, S. Ballesta, E.J. Perea.
Uptake and intracellular activity of HMR 3647 in human phagocytic and nonphagocytic cells. 38th,
[59.]
H.E. Scholtz, E. Sultan, D. Wessels, A.F. Hund, V. Passot, A. Renoux, N. Van Neikerk.
HMR 3647, a new ketolide antimicrobial, does not affect the reliabitlity of low-dose, triphasis oral contraceptives. 39th,
[60.]
M. Aubier, P.M. Aldons, A. Leak, D.D. Mckeith, B. Leroy, R. Manickam, et al.
Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute exacerbations of chronic bronchitis in patients with COPD. 40th,
[61.]
S.R. Norrby, P.A. Bacart, W.J. Rabie, O.F. Mueller, B. Leroy, R. Manickam, et al.
Efficacy of 5 days telithromycin vs. 10 days penicillin V in the treatment of pharyngitis in adults. 40th,
[62.]
L. Hagberg, A. Torres, D.J. Rensburg, B. Leroy, R. Manickam, E. Ruuth.
Efficacy and tolerability of telithromycin vs high-dose amoxicillin in the treatment of comunity-acquired pneumonia. 40th,
[63.]
M. Aubier, P.M. Aldons, A. Leak, D.D. McKeith, B. Leroy, M. Rangaraju, et al.
Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin, for the treatment of acute sinusitis. 40th,
[64.]
F.P. Tally, M. Zeckel, M.M. Wasilewski, C. Carini, C.L. Berman, G.L. Drusano, et al.
Daptomycin: a novel agent for Gram-positive infections.
Exp Opin Invest Drugs, 8 (1999), pp. 1.223-1.238
[65.]
P. Canepari, M. Boaretti, Lleo M. Del Mar, G. Satta.
Lipoteichoic acid as a new target for activity of antibiotics: Mode of action of daptomycin (LY146032).
Antimicrob Agents Chemother, 34 (1990), pp. 1.220-1.226
[66.]
W.E. Alborn, N.E. Allen, D.A. Preston.
Daptomycin disrupts membrane potential in growing Staphylococcus aureus.
Antimicrob Agents Chemother, 35 (1991), pp. 2.639-2.642
[67.]
H. Hanberger.
Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial Killing, postantibiotic effect and effective regrowth time.
Scan J Infect Dis, 81 (1992), pp. 1-52
[68.]
M.F. Tripodi, L.E. Adinolfi, R. Utili, A. Marrone, G. Ruggiero.
Influence of subinhibitory concentrations of loracarberf (Ly 163892) and daptomycin (LY 146032) on bacterial phagocytosis, killing and serum sensitivity.
J Antimicrob Chemother, 26 (1990), pp. 491-501
[69.]
G.W. Kaatz, S.M. Seo, T.S. Lundstrom.
Development of daptomycin resistance in experimental Staphylococcus aureus endocarditis. 33th,
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
